Press Releases - Any - 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2021 News March 30, 2021 argenx announces Annual General Meeting of Shareholders on May 11, 2021 argenx SE today announced that an annual general meeting of shareholders will be held at 10:00 a.m. CEST on Tuesday May 11, 2021 at the Hilton Read News March 4, 2021 argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update argenx today reported financial results for the full year 2020 and provided a fourth quarter business update. Read News March 2, 2021 argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis argenx today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Read News February 25, 2021 argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021 argenx today announced that it will host a conference call and audio webcast on March 4, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its full year 2020 financial results and provide a fourth quarter business update. Read News February 5, 2021 argenx announces closing of global offering argenx SE announced today the closing of its previously announced global offering of an aggregate of 3,593,750 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 468,750 ordinary... Read News February 4, 2021 argenx announces full exercise of underwriters’ option to purchase additional ADSs argenx SE announced today that the underwriters of its previously announced global offering of ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)) have exercised their option to purchase 468,750 additional ADSs in full on the same terms and conditions as the... Read News February 2, 2021 argenx raises $1.0 billion in gross proceeds in a global offering argenx SE announced today the pricing of a global offering of ordinary shares represented by American Depository Shares (ADSs) in the United States and certain other countries outside of European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area and... Read News February 2, 2021 argenx Issues Statement Concerning Efgartigimod argenx SE today provided a statement in response to news from Immunovant regarding a voluntary pause of dosing in its ongoing trials for IMVT-1401, an FcRn antagonist. Read News February 1, 2021 argenx announces launch of proposed global offering argenx SE announced today that it has commenced a global offering of $750 million (approximately €618 million) of ordinary shares, which may be represented by American Depository Shares (“ADSs”). Read News February 1, 2021 argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis argenx today announced its plan to continue enrollment in the ADHERE trial evaluating subcutaneous (SC) efgartigimod (co-formulated with Halozyme's Read News January 8, 2021 argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline argenx today announced its 2021 corporate priorities and highlighted recent achievements from its late-stage immunology pipeline driven by its FcRn Read News January 6, 2021 argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China argenx SE and Zai Lab Limited today announced an exclusive license agreement for the development and commercialization of efgartigimod in Greater Read Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 … Next page Next › Last page Last »
News March 30, 2021 argenx announces Annual General Meeting of Shareholders on May 11, 2021 argenx SE today announced that an annual general meeting of shareholders will be held at 10:00 a.m. CEST on Tuesday May 11, 2021 at the Hilton Read
News March 4, 2021 argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update argenx today reported financial results for the full year 2020 and provided a fourth quarter business update. Read
News March 2, 2021 argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis argenx today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Read
News February 25, 2021 argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021 argenx today announced that it will host a conference call and audio webcast on March 4, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its full year 2020 financial results and provide a fourth quarter business update. Read
News February 5, 2021 argenx announces closing of global offering argenx SE announced today the closing of its previously announced global offering of an aggregate of 3,593,750 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 468,750 ordinary... Read
News February 4, 2021 argenx announces full exercise of underwriters’ option to purchase additional ADSs argenx SE announced today that the underwriters of its previously announced global offering of ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)) have exercised their option to purchase 468,750 additional ADSs in full on the same terms and conditions as the... Read
News February 2, 2021 argenx raises $1.0 billion in gross proceeds in a global offering argenx SE announced today the pricing of a global offering of ordinary shares represented by American Depository Shares (ADSs) in the United States and certain other countries outside of European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area and... Read
News February 2, 2021 argenx Issues Statement Concerning Efgartigimod argenx SE today provided a statement in response to news from Immunovant regarding a voluntary pause of dosing in its ongoing trials for IMVT-1401, an FcRn antagonist. Read
News February 1, 2021 argenx announces launch of proposed global offering argenx SE announced today that it has commenced a global offering of $750 million (approximately €618 million) of ordinary shares, which may be represented by American Depository Shares (“ADSs”). Read
News February 1, 2021 argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis argenx today announced its plan to continue enrollment in the ADHERE trial evaluating subcutaneous (SC) efgartigimod (co-formulated with Halozyme's Read
News January 8, 2021 argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline argenx today announced its 2021 corporate priorities and highlighted recent achievements from its late-stage immunology pipeline driven by its FcRn Read
News January 6, 2021 argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China argenx SE and Zai Lab Limited today announced an exclusive license agreement for the development and commercialization of efgartigimod in Greater Read